Solasia Pharma K.K. (FRA:9SO)

Germany · Delayed Price · Currency is EUR

0.163

+0.006 (3.82%)

Last updated: Dec 4, 2025, 8:00 AM CET

-44.56% (1Y)

Market Cap	47.42M
Revenue (ttm)	1.88M
Net Income (ttm)	-10.34M
Shares Out	n/a
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.163
Previous Close	0.157
Day's Range	0.163 - 0.163
52-Week Range	0.146 - 0.294
Beta	n/a
RSI	51.47
Earnings Date	Feb 12, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2006

Employees 23

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 9SO

Full Company Profile

Financial Performance

In 2024, Solasia Pharma K.K.'s revenue was 316.00 million, a decrease of -48.78% compared to the previous year's 617.00 million. Losses were -1.94 billion, 74.6% more than in 2023.

Financial numbers in JPY Financial Statements

News

There is no news available yet.